166 related articles for article (PubMed ID: 27225751)
1. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.
Babyshkina N; Vtorushin S; Zavyalova M; Patalyak S; Dronova T; Litviakov N; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
Clin Exp Med; 2017 Aug; 17(3):383-393. PubMed ID: 27225751
[TBL] [Abstract][Full Text] [Related]
2. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.
Babyshkina N; Vtorushin S; Dronova T; Patalyak S; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
Clin Exp Med; 2019 Nov; 19(4):547-556. PubMed ID: 31562548
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
Markiewicz A; Wełnicka-Jaśkiewicz M; Skokowski J; Jaśkiewicz J; Szade J; Jassem J; Zaczek AJ
PLoS One; 2013; 8(8):e72219. PubMed ID: 23951298
[TBL] [Abstract][Full Text] [Related]
4. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
5. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
7. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
Hertz DL; Henry NL; Kidwell KM; Thomas D; Goddard A; Azzouz F; Speth K; Li L; Banerjee M; Thibert JN; Kleer CG; Stearns V; Hayes DF; Skaar TC; Rae JM
Physiol Genomics; 2016 Sep; 48(9):688-98. PubMed ID: 27542969
[TBL] [Abstract][Full Text] [Related]
8. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.
Houtsma D; de Groot S; Baak-Pablo R; Kranenbarg EM; Seynaeve CM; van de Velde CJH; Böhringer S; Kroep JR; Guchelaar H-; Gelderblom H
Sci Rep; 2021 Feb; 11(1):3249. PubMed ID: 33547330
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
10. Loss of Estrogen-Regulated
Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
[TBL] [Abstract][Full Text] [Related]
11. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
[TBL] [Abstract][Full Text] [Related]
12. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
13. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
14. Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients.
Allahloubi NMA; Zekri AN; Ragab M; Mohanad M; Ahmed OS; Eid S; Ghareeb M; Gouda I; Bahnassy AA
Biochem Genet; 2022 Dec; 60(6):1963-1985. PubMed ID: 35182276
[TBL] [Abstract][Full Text] [Related]
15. Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
Singer CF; ; Holst F; Steurer S; Burandt EC; Lax SF; Jakesz R; Rudas M; Stöger H; Greil R; ; Sauter G; Filipits M; ; Simon R; Gnant M;
Clin Cancer Res; 2022 Sep; 28(18):4112-4120. PubMed ID: 35920686
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients.
Hato Y; Kondo N; Yoshimoto N; Endo Y; Asano T; Dong Y; Nishimoto M; Takahashi S; Fujii Y; Nakanishi R; Toyama T
Int J Clin Oncol; 2016 Jun; 21(3):539-47. PubMed ID: 26482374
[TBL] [Abstract][Full Text] [Related]
18. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
Nielsen KV; Ejlertsen B; Müller S; Møller S; Rasmussen BB; Balslev E; Lænkholm AV; Christiansen P; Mouridsen HT
Breast Cancer Res Treat; 2011 Jun; 127(2):345-55. PubMed ID: 20556506
[TBL] [Abstract][Full Text] [Related]
19. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]